Table 1.

Demographics and baseline characteristics stratified by age ≥ 60 and < 60 years

Demographics	AWARD-CHN1				AWARD-CHN2
	1.5 mg		0.75 mg		1.5 mg		0.75 mg
	Age ≥ 60 years (n = 54)	Age < 60 years (n = 130)	Age ≥ 60 years (n = 52)	Age < 60 years (n = 134)	Age ≥ 60 years (n = 59)	Age < 60 years (n = 141)	Age ≥ 60 years (n = 57)	Age < 60 years (n = 139)
Gender, n (%)
Male	30 (55.6)	79 (60.8)	22 (42.3)	85 (63.4)	31 (52.5)	86 (61.0)	37 (64.9)	83 (59.7)
Female	24 (44.4)	51 (39.2)	30 (57.7)	49 (36.6)	28 (47.5)	55 (39.0)	20 (35.1)	56 (40.3)
Age, years (mean ± SD)	64.1 ± 3.2	48.1 ± 8.6	64.8 ± 3.4	49.5 ± 8.1	65.6 ± 3.9	49.9 ± 8.0	65.8 ± 4.5	49.3 ± 7.3
Diabetes duration, years (mean ± SD)	6.2 ± 6.1	3.1 ± 3.6	5.2 ± 5.5	2.5 ± 2.9	9.7 ± 4.9	6.9 ± 4.2	10.5 ± 5.7	6.7 ± 4.8
BMI, kg/m2 (mean ± SD)	25.4 ± 2.7	25.6 ± 3.4	26.1 ± 3.6	26.0 ± 3.3	25.3 ± 2.8	26.1 ± 3.3	25.7 ± 2.9	26.5 ± 3.4
Weight, kg (mean ± SD)	67.6 ± 10.1	70.5 ± 10.9	68.3 ± 11.6	71.7 ± 12.1	68.0 ± 9.7	73.6 ± 12.7	71.5 ± 10.3	73.9 ± 12.6
HbA1c, % (mean ± SD)	7.9 ± 0.8	8.0 ± 1.0	8.0 ± 1.0	8.1 ± 1.0	8.2 ± 1.3	8.5 ± 1.1	8.3 ± 1.1	8.3 ± 1.1
FBG, mmol/L (mean ± SD)	9.4 ± 2.3	9.5 ± 2.7	9.0 ± 2.2	9.4 ± 2.6	8.9 ± 2.2	9.9 ± 2.7	9.7 ± 2.2	9.7 ± 2.3
HOMA2-%B, mean (range), %	36.9 (7.5–89.9)	39.2 (7.1–135.7)	40.8 (10.5–93.6)	41.3 (6.0–119.1)	42.7 (5.4–152.6)	34. 4 (7.5–100.9)	35.9 (11.2–98.9)	37.1 (7.3–136.9)
OAM regimen, n (%)
Metformin only	NA				24 (40.7)	62 (44.0)	17 (29.8)	66 (47.8)
Sulfonylurea only	NA				10 (16.9)	18 (12.8)	11 (19.3)	16 (11.6)
Metformin and sulfonylurea	NA				25 (42.4)	61 (43.3)	29 (50.9)	56 (40.6)

BMI body mass index, FBG fasting blood glucose, HbA1c glycosylated hemoglobin A1c, HOMA2-%B Updated Homeostasis Model Assessment of β-cell function, NA not applicable, OAM oral antihyperglycemia medication